🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07388797
Recruiting Observational

Impact of Serum Progesterone Levels on Embryo Transfer Day on Clinical Pregnancy

NCT07388797 · tracked via the Priya Life Science China tracker
Sponsor
Chinese University of Hong Kong
Phase
Observational
Started
2026-01-20
Last updated
2026-05-11

Condition(s) studied

Reproductive Issues

Study summary

Hypotheses:

We hypothesize that serum progesterone levels on the day of embryo transfer in HRT-FET cycles are positively associated with clinical pregnancy rates.

Aims:

To evaluate the relationship between serum progesterone levels on embryo transfer day and clinical pregnancy outcomes in frozen-thawed embryo transfer cycles using hormone replacement therapy (HRT).

Primary outcome:

To compare the incidence of clinical pregnancy outcome in those infertility patients undergoing frozen embryo transfer with caterized Progesterone level on the day of embryo transfer

Secondary outcomes:

Biochemical pregnancy rate. Implantation rate. Early pregnancy loss rate. Ectopic pregnancy rate.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
42 Years
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing FET cycles * Infertility patients aged \>18 years old and \< 42 years old * BMI \< 30 kg/m2 * Transfer of at least one good-quality embryo. Exclusion Criteria: * Severe endocrine disorders (e.g., thyroid dysfunction, premature ovarian failure). * Severe uterine factors without treatment (severe endometriosis, extensive or subendometrial fibroid, uterine adherent, endometrial polyps)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Chinese University of Hong Kong Hong Kong China Recruiting

More Chinese University of Hong Kong trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388797 on ClinicalTrials.gov ↗ ← All trials in China